Department of Urology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Department of Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
World J Urol. 2019 Mar;37(3):445-455. doi: 10.1007/s00345-018-2546-6. Epub 2018 Nov 17.
An increasing interest in percutaneous ablation of renal tumors has been caused by the increasing incidence of SRMs, the trend toward minimally invasive nephron-sparing treatments and the rapid development of local ablative technologies. In the era of shared decision making, patient preference for non-invasive treatments also leads to an increasing demand for image-guided ablation. Although some guidelines still reserve ablation for poor surgical candidates, indications may soon expand as evidence for the use of the two most validated local ablative techniques, cryoablation (CA) and radiofrequency ablation (RFA), is accumulating. Due to the collaboration between experts in the field in biomedical engineering, urologists, interventional radiologists and radiation oncologists, the improvements in ablation technologies have been evolving rapidly in the last decades, resulting in some new emerging types of ablations.
A literature search was conducted to identify original research articles investigating the clinical outcomes of new emerging technologies, percutaneous MWA, percutaneous IRE and SABR, in patients with primary cT1 localized renal cell cancer.
Due to the collaboration between experts in the field in biomedical engineering, urologists, interventional radiologists and radiation oncologists, the improvements in ablation technologies have been evolving rapidly in the last decades. New emerging technologies such as microwave ablation (MWA), irreversible electroporation (IRE) and stereotactic ablative radiotherapy (SABR) seem to be getting ready for prime time.
This topical paper describes the new emerging technologies for cT1 localized renal cell cancer and investigates how they compare to CA and RFA.
随着偶发癌（SRMs）发病率的增加、微创保肾治疗方法的发展趋势以及局部消融技术的快速发展，人们对肾肿瘤经皮消融的兴趣日益浓厚。在共同决策时代，患者对非侵入性治疗的偏好也导致对影像引导消融的需求不断增加。虽然一些指南仍然将消融术保留给手术效果不佳的患者，但随着对两种最有效的局部消融技术（冷冻消融术（CA）和射频消融术（RFA））使用证据的积累，适应证可能很快会扩大。由于生物医学工程、泌尿科医生、介入放射科医生和放射肿瘤学家领域专家之间的合作，过去几十年来消融技术的改进迅速发展，导致了一些新的消融技术出现。
进行了文献检索，以确定调查新技术（经皮微波消融术、经皮不可逆电穿孔术和立体定向消融放疗）在原发性 cT1 局限性肾细胞癌患者中临床结局的原始研究文章。
由于生物医学工程、泌尿科医生、介入放射科医生和放射肿瘤学家领域专家之间的合作，过去几十年来消融技术的改进迅速发展。微波消融术（MWA）、不可逆电穿孔术（IRE）和立体定向消融放疗（SABR）等新出现的技术似乎即将崭露头角。
本文介绍了用于 cT1 局限性肾细胞癌的新兴技术，并探讨了它们与 CA 和 RFA 的比较。
